Gilead Collaborates with Kyverna Therapeutics on T-cell Therapies

By Pratika Pahwa

Pharma Deals Review: Vol 2020 Issue 1 (Table of Contents)

Published: 31 Jan-2020

DOI: 10.3833/pdr.v2020.i1.2509     ISSN: 1756-7874

Section: Licensing



Adding depth to its portfolio, Gilead has entered into a licensing agreement with Kyverna Therapeutics to develop T cell therapies for the treatment of autoimmune diseases...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details